Education
About Us
Working with TipRanks
Follow Us
Michael Pruitt Insider Profile
4 Followers
Michael Pruitt, CEO, Chairman, Director at Sonnet BioTherapeutics Holdings, holds 12.14K shares in Imac Holdings (Ticker: BACK), holds 30.00K shares in Fresh Vine Wine Inc (Ticker: VINE), holds 64.54K shares in Amergent Hospitality Group (Ticker: AMHGQ).
Michael Pruitt Sonnet BioTherapeutics Holdings (SONN)CEO, Chairman, Director
Sonnet BioTherapeutics Holdings (SONN)
CEO, Chairman, Director
Ranked #98,741 out of 100,956 Corporate Insiders
Profitable Transactions
7 out of 47 Profitable Transactions
Average Return
-46.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Michael Pruitt holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:May 30, 2014 - May 30, 2015
Return:+76.90%
The most profitable trade made by Michael Pruitt
Michael Pruitt's Trading History
Sonnet BioTherapeutics Holdings
Mar 24, 2020
CEO, Chairman, Director
Uninformative Buy
―
$94.60K
Imac Holdings
Jan 02, 2025
Director
Uninformative Buy
―
$6.80K
Amergent Hospitality Group
Dec 21, 2022
CEO, Director
Informative Buy
910.00
$6.45K
Fresh Vine Wine Inc
Apr 04, 2023
Director
Uninformative Buy
―
$15.87K
Forward Industries
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Michael Pruitt's performance on stock
You May Also Like
Michael Pruitt insider profile FAQ
What is the percentage of profitable transactions made by Michael Pruitt?
The percentage of profitable transactions made by Michael Pruitt is 15%.
What is the average return per transaction made by Michael Pruitt?
The average return per transaction made by Michael Pruitt is -46.70%.
What stocks does Michael Pruitt hold?
Michael Pruitt holds: SONN, BACK, AMHGQ, VINE, FORD stocks.
What was Michael Pruitt’s latest transaction?
Michael Pruitt latest transaction was an Uninformative Buy of ―.
What was Michael Pruitt's most profitable transaction?
Michael Pruitt’s most profitable transaction was an Informative Buy of SONN stock on May 30, 2014. The return on the trade was 76.90%.
What is Michael Pruitt's role in Sonnet BioTherapeutics Holdings?
Michael Pruitt's role in Sonnet BioTherapeutics Holdings is CEO, Chairman, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.